GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Prestige BioPharma Ltd (XKRX:950210) » Definitions » Other Income (Expense)

Prestige BioPharma (XKRX:950210) Other Income (Expense) : ₩3,444 Mil (TTM As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Prestige BioPharma Other Income (Expense)?

Prestige BioPharma's other income expense for the Prestige BioPharma's pretax income for the three months ended in Dec. 2024 was ₩350 Mil. Its other income expense for the trailing twelve months (TTM) ended in Dec. 2024 was ₩3,444 Mil.

Prestige BioPharma Other Income (Expense) Historical Data

The historical data trend for Prestige BioPharma's Other Income (Expense) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prestige BioPharma Other Income (Expense) Chart

Prestige BioPharma Annual Data
Trend Jun20 Jun21 Jun22 Jun23 Jun24
Other Income (Expense)
-4,548.49 10,875.12 -154,843.12 -12,675.47 3,062.68

Prestige BioPharma Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Other Income (Expense) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.34 316.97 2,682.48 93.95 350.12

Prestige BioPharma Other Income (Expense) Calculation

Other income expense includes minority interest. Minority interest is a significant but non-controlling ownership of less than 50% of a company's voting shares by either an investor or another company.

Other Income (Expense) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩3,444 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Prestige BioPharma  (XKRX:950210) Other Income (Expense) Explanation

Minority interest is reported on the consolidated income statement as a share of profit belonging to minority shareholders.

Prestige BioPharma Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Prestige BioPharma Ltd (XKRX:950210) » Definitions » Other Income (Expense)
Comparable Companies
XKRX:226950 XKRX:005690 XKRX:085660 XKRX:005250 XKRX:347850 XKRX:115450 XKRX:053030 XKRX:048410 XKRX:358570 XKRX:086900 VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
N/A
Address
2 Science Park Drive No. 04-13/14, Ascent Tower B, Singapore Science Park, Singapore, SGP, 118222
Website
https://www.prestigebiopharma.com
Prestige BioPharma Ltd is a biopharmaceutical company. The company is focused on the development of biosimilars and new antibody therapeutics. It focuses on oncology and immune disorders, developing new and similar antibody drugs for solid tumor, pancreatic cancer, and arthritis.

Prestige BioPharma Headlines

No Headlines